FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2002065456> ?p ?o ?g. }

• W2002065456 endingPage "363" @default.
• W2002065456 startingPage "356" @default.
• W2002065456 abstract "Pulmonary permeability oedema is a frequent complication in a number of life-threatening lung conditions, such as ALI and ARDS. Apart from ventilation strategies, no specific therapy yet exists for treatment of these potentially fatal illnesses. The oedema-reducing capacity of the lectin-like domain of TNF (TIP) and of synthetic peptides, mTIP and hTIP, which mimic the TIP domain of mouse and human TNF, have been demonstrated in various studies in rodents. Cell-based electrophysiological studies have revealed that the alveolar fluid clearing capacity of TNF and the TIP peptides is due to activation of the amiloride-sensitive Na+ current in alveolar epithelial cells and that the primary site of action is on the apical side of these cells. AP301, a synthetic cyclic peptide mimicking the TIP domain of human TNF is currently undergoing clinical trials as a therapy for pulmonary permeability oedema. AP301 has been shown to improve alveolar liquid clearance and lung function in a porcine model of ALI. For non-clinical regulatory assessment, dog, pig and rat are standard animal models; accordingly, pre-clinical toxicological and pharmacological safety studies have been conducted with AP301 in dogs and rats. Hitherto, no studies have assessed the pharmacodynamic effect of AP301 on primary canine or porcine type II AEC. The current study describes the effect of AP301 on the amiloride-sensitive Na+ current in type II AEC isolated from dog, pig and rat lungs. In whole cell patch clamp experiments with dog type II AEC, an increase in the amiloride-sensitive Na+ current from 3.7 pA to 49.4 pA was observed in the presence of AP301; in pig type II AEC, an increase from 10.0 pA to 159.6 pA was observed, and in rat AEC, from 6.9 pA to 62.4 pA. In whole cell patch clamp experiments in A549 cells, AP301-induced enhancement of the amiloride-sensitive current was eliminated when Na+ in the bath solution was replaced with N-methyl-d-glucamine (NMDG), and when the cells were pre-incubated with 5-aminoimidazole-4-carboxamide-1-ß-d-ribofuranoside (AICAR), an inhibitor of ENaC, but enhancement was unaffected by addition of cyclic nucleotide-gated (CNG) channel inhibitors Zn2+ or l-cis-diltiazem prior to AP301. These results provide strong evidence that AP301 activates the amiloride-sensitive Na+ current through ENaC in type II AEC from dog, pig and rat. To our knowledge, this is the first cell-based analysis of the oedema-clearing effect of AP301 observed in the porcine model of pulmonary oedema. Furthermore, the results validate the dog and pig models in non-clinical assessment of AP301." @default.
• W2002065456 created "2016-06-24" @default.
• W2002065456 creator A5013959435 @default.
• W2002065456 creator A5025242563 @default.
• W2002065456 creator A5026532272 @default.
• W2002065456 creator A5026810346 @default.
• W2002065456 creator A5027244605 @default.
• W2002065456 creator A5052598018 @default.
• W2002065456 creator A5063033116 @default.
• W2002065456 creator A5067067730 @default.
• W2002065456 creator A5073702210 @default.
• W2002065456 creator A5088951200 @default.
• W2002065456 date "2013-06-01" @default.
• W2002065456 modified "2023-10-18" @default.
• W2002065456 title "AP301, a synthetic peptide mimicking the lectin-like domain of TNF, enhances amiloride-sensitive Na+ current in primary dog, pig and rat alveolar type II cells" @default.
• W2002065456 cites W1906410030 @default.
• W2002065456 cites W1966647002 @default.
• W2002065456 cites W1976830450 @default.
• W2002065456 cites W1986296119 @default.
• W2002065456 cites W1994203972 @default.
• W2002065456 cites W1996692538 @default.
• W2002065456 cites W2009667219 @default.
• W2002065456 cites W2013778395 @default.
• W2002065456 cites W2027862991 @default.
• W2002065456 cites W2040368687 @default.
• W2002065456 cites W2046383193 @default.
• W2002065456 cites W2052571887 @default.
• W2002065456 cites W2079894038 @default.
• W2002065456 cites W2081692773 @default.
• W2002065456 cites W2084161778 @default.
• W2002065456 cites W2087499467 @default.
• W2002065456 cites W2110707896 @default.
• W2002065456 cites W2113640645 @default.
• W2002065456 cites W2116375030 @default.
• W2002065456 cites W2120245762 @default.
• W2002065456 cites W2134906082 @default.
• W2002065456 cites W2142806464 @default.
• W2002065456 cites W2144304154 @default.
• W2002065456 cites W2156876013 @default.
• W2002065456 cites W2158310716 @default.
• W2002065456 cites W2170476499 @default.
• W2002065456 cites W2171493300 @default.
• W2002065456 cites W2171619939 @default.
• W2002065456 cites W2241461566 @default.
• W2002065456 cites W2315776734 @default.
• W2002065456 doi "https://doi.org/10.1016/j.pupt.2012.12.011" @default.
• W2002065456 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3646188" @default.
• W2002065456 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23313096" @default.
• W2002065456 hasPublicationYear "2013" @default.
• W2002065456 type Work @default.
• W2002065456 sameAs 2002065456 @default.
• W2002065456 citedByCount "23" @default.
• W2002065456 countsByYear W20020654562013 @default.
• W2002065456 countsByYear W20020654562014 @default.
• W2002065456 countsByYear W20020654562015 @default.
• W2002065456 countsByYear W20020654562017 @default.
• W2002065456 countsByYear W20020654562018 @default.
• W2002065456 countsByYear W20020654562019 @default.
• W2002065456 countsByYear W20020654562020 @default.
• W2002065456 countsByYear W20020654562022 @default.
• W2002065456 countsByYear W20020654562023 @default.
• W2002065456 crossrefType "journal-article" @default.
• W2002065456 hasAuthorship W2002065456A5013959435 @default.
• W2002065456 hasAuthorship W2002065456A5025242563 @default.
• W2002065456 hasAuthorship W2002065456A5026532272 @default.
• W2002065456 hasAuthorship W2002065456A5026810346 @default.
• W2002065456 hasAuthorship W2002065456A5027244605 @default.
• W2002065456 hasAuthorship W2002065456A5052598018 @default.
• W2002065456 hasAuthorship W2002065456A5063033116 @default.
• W2002065456 hasAuthorship W2002065456A5067067730 @default.
• W2002065456 hasAuthorship W2002065456A5073702210 @default.
• W2002065456 hasAuthorship W2002065456A5088951200 @default.
• W2002065456 hasBestOaLocation W20020654562 @default.
• W2002065456 hasConcept C126322002 @default.
• W2002065456 hasConcept C142724271 @default.
• W2002065456 hasConcept C178790620 @default.
• W2002065456 hasConcept C185592680 @default.
• W2002065456 hasConcept C2776348555 @default.
• W2002065456 hasConcept C2777714996 @default.
• W2002065456 hasConcept C2779608910 @default.
• W2002065456 hasConcept C2779854577 @default.
• W2002065456 hasConcept C537181965 @default.
• W2002065456 hasConcept C71924100 @default.
• W2002065456 hasConcept C98274493 @default.
• W2002065456 hasConceptScore W2002065456C126322002 @default.
• W2002065456 hasConceptScore W2002065456C142724271 @default.
• W2002065456 hasConceptScore W2002065456C178790620 @default.
• W2002065456 hasConceptScore W2002065456C185592680 @default.
• W2002065456 hasConceptScore W2002065456C2776348555 @default.
• W2002065456 hasConceptScore W2002065456C2777714996 @default.
• W2002065456 hasConceptScore W2002065456C2779608910 @default.
• W2002065456 hasConceptScore W2002065456C2779854577 @default.
• W2002065456 hasConceptScore W2002065456C537181965 @default.
• W2002065456 hasConceptScore W2002065456C71924100 @default.
• W2002065456 hasConceptScore W2002065456C98274493 @default.
• W2002065456 hasIssue "3" @default.
• W2002065456 hasLocation W20020654561 @default.
• W2002065456 hasLocation W20020654562 @default.

• next